Compounded Semaglutide: What It Is, How It Works, and What to Expect

*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*

---

If you have heard about semaglutide, the active ingredient in Ozempic and Wegovy, and wondered whether there is a more affordable way to access it, you are not alone. Compounded semaglutide has become one of the most searched topics in weight loss medicine. This guide breaks down exactly what it is, how it works, who it is right for, and what you can realistically expect.

---

What Is Compounded Semaglutide?

Semaglutide is the active ingredient in FDA-approved brand-name medications like Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Both are manufactured by Novo Nordisk and have been widely prescribed since 2021.

Compounded semaglutide is a GLP-1 receptor agonist prepared by a licensed compounding pharmacy rather than a drug manufacturer. It is not the same product as Ozempic or Wegovy and is not FDA-approved. It is mixed, measured, and filled to order, often with customized dosing options that standard commercial products do not offer.

Important distinction: Compounded medications are not FDA-approved. They are prepared under FDA oversight through regulations that govern compounding pharmacies, but they go through a different pathway than brand-name drugs. This is a real difference worth understanding before you start.

How Is It Different from Ozempic or Wegovy?

Ozempic and Wegovy contain semaglutide as their active ingredient. Compounded semaglutide also contains semaglutide as its active ingredient. What differs is the manufacturing process, the form it comes in, and the cost.

• Brand-name products are mass-manufactured to uniform specifications, carry FDA approval, and are covered (sometimes) by insurance.
• Compounded semaglutide is prepared in licensed pharmacies, is not FDA-approved, and is typically available at a significantly lower out-of-pocket cost.

What compounded semaglutide is not: it is not "the same as Ozempic," and we will not tell you it is. It is a compounded GLP-1 receptor agonist, prepared by licensed pharmacists at clinically relevant doses, under a separate regulatory pathway.

---

How Does Compounded Semaglutide Work?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). To understand why that matters, it helps to know what GLP-1 actually does in your body.

The GLP-1 Mechanism, Explained Simply

GLP-1 is a hormone your gut naturally releases after you eat. It does three main things:

1. Signals your pancreas to release insulin (only when blood sugar is elevated, so it does not cause dangerous low blood sugar in most people)
2. Slows down how quickly your stomach empties, meaning food stays in your stomach longer, and you feel full longer
3. Sends "I'm full" signals to your brain, specifically to appetite-control regions that regulate hunger

In people with obesity, this GLP-1 signaling is often blunted. Semaglutide works by mimicking and amplifying this natural hormone, keeping the signal active for much longer than your body's own GLP-1 would.

A 2021 review by Ard et al., published in *Advances in Therapy* (PMID: 33977495), summarized this well: GLP-1 receptor agonists reduce appetite, slow gastric emptying, and promote feelings of fullness, working through both central (brain) and peripheral (gut) pathways to reduce caloric intake.

What This Means in Practice

Most people taking semaglutide report that food just is not as interesting as it used to be. The "food noise" (the background mental chatter about snacking, what to eat next, cravings) quiets significantly. You eat less, not because you are white-knuckling through hunger, but because the hunger signal itself is weaker.

This is different from traditional stimulant-based weight loss drugs or strict calorie-counting approaches. It works with your biology, not against it.

---

Is Compounded Semaglutide Safe?

This is the question most people ask first, and it is the right question.

FDA Compounding Regulations

Compounding pharmacies in the United States are regulated under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 503B outsourcing facilities are held to higher standards: they are inspected by the FDA and must follow Current Good Manufacturing Practices (cGMP), similar to commercial drug manufacturers.

Prescriptions written by providers in Prescriva's affiliated network are filled by licensed compounding pharmacies. This means your medication is:

• Prepared under strict quality controls
• Subject to FDA inspection
• Tested for potency, sterility, and purity

Known Side Effects

Semaglutide, whether brand-name or compounded, has a well-established side effect profile. The most common side effects are gastrointestinal:

• Nausea (most common, especially in the first few weeks)
• Vomiting
• Diarrhea
• Constipation

In the STEP 1 clinical trial (Wilding et al., NEJM 2021, PMID: 33567185), GI side effects were reported in about 74% of semaglutide participants, compared to 48% in the placebo group. Most were mild to moderate and decreased over time as the body adjusted.

Serious but Rare Risks

Semaglutide carries a boxed warning for thyroid C-cell tumors, based on animal studies. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not recommended during pregnancy.

This is not medical advice. Consult your healthcare provider before starting any medication.

---

Who Qualifies for Compounded Semaglutide?

Not everyone is a candidate, and that is by design. Clinical guidelines, and Prescriva's licensed providers, follow evidence-based criteria.

General Eligibility

You may qualify if you meet one of the following:

• BMI of 30 or higher (classified as obesity)
• BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea

These are the same criteria used in the landmark STEP clinical trials and align with FDA-approved labeling for semaglutide 2.4 mg (Wegovy).

Who Should Not Use It

Compounded semaglutide is not appropriate for everyone. You should not use it if you have:

• Personal or family history of medullary thyroid carcinoma or MEN 2
• A history of pancreatitis
• Severe kidney or liver disease (without close medical supervision)
• Current pregnancy or plans to become pregnant
• Allergy to semaglutide or any component of the formulation

Your Prescriva provider will review your health history during your online assessment to determine whether this medication is appropriate for you.

---

How to Get Compounded Semaglutide Online

Getting started with Prescriva is designed to be simple, private, and fast. Here is what the process looks like.

Step 1: Complete Your Free Online Assessment

You fill out a health questionnaire covering your medical history, current medications, weight history, and goals. This takes about 10 minutes and is completely private.

Step 2: A Licensed Provider Reviews Your Case

A licensed healthcare provider, either a clinician or nurse practitioner, reviews your assessment, usually within 24 hours. They check your eligibility, flag any contraindications, and determine the right starting dose for you.

Step 3: Your Prescription Is Sent to a Licensed Compounding Pharmacy

If approved, your prescription goes directly to a state-licensed 503A compounding pharmacy. No trips to a pharmacy. No waiting in line.

Step 4: Your Medication Ships to Your Door

Your compounded semaglutide is shipped directly to you in discreet packaging, typically within a few business days.

Step 5: Ongoing Check-Ins

Your Prescriva provider monitors your progress and can adjust your dose as needed. This is a supervised medical program, not a one-and-done transaction.

---

What to Expect: Timeline and Results

One of the most common questions is: "How long until I see results?"

The First Few Weeks

Most people start at a low dose (typically 0.25 mg/week) to minimize GI side effects. During this period, you may notice reduced appetite but may not see dramatic weight changes yet. Your body is adjusting.

Nausea is most common in weeks 1-4. Eating smaller portions, avoiding greasy or spicy foods, and taking your injection in the evening (so any nausea happens while you sleep) can help.

Weeks 4-12: The Dose Escalation Phase

Doses are typically increased every 4 weeks. As the dose increases, appetite suppression becomes more pronounced. Most people start seeing meaningful weight changes during this phase.

Months 3-6: Steady Progress

Published clinical research on the branded, FDA-approved formulation provides useful context. In the STEP 1 trial (Wilding et al., NEJM 2021, PMID: 33567185), participants taking branded semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks with lifestyle support, compared to 2.4% in the placebo group.

For people with type 2 diabetes, the STEP 2 trial (Davies et al., Lancet 2021, PMID: 33667417) showed an average weight loss of 9.6% at 68 weeks with branded semaglutide 2.4 mg.

Important: These results are from clinical trials of branded, FDA-approved semaglutide (Wegovy). Compounded semaglutide has not been separately studied in equivalent clinical trials, and these results should not be assumed to apply to compounded formulations. Results may vary. Individual results depend on adherence to treatment and lifestyle changes. These trial figures represent averages. Some people lose more, some less. Diet, physical activity, sleep, and stress all play meaningful roles in outcomes.

The Role of Lifestyle

Semaglutide is a powerful tool, but the STEP trials paired it with lifestyle counseling. The medication quiets hunger; your choices about what you eat and how you move determine how much of that advantage you convert into lasting change. Think of it as tilting the playing field: the work is still yours to do, but it becomes much more manageable.

---

How Much Does Compounded Semaglutide Cost?

Brand-name Wegovy carries a list price of over $1,300/month without insurance. Even with coverage, many people face high co-pays or prior authorization barriers. Compounded semaglutide offers a dramatically more accessible price point.

Prescriva Pricing

Compounded semaglutide at Prescriva starts at $159/month.

That price includes:

• Your provider consultation
• Your prescription
• The medication itself
• Shipping

These items are bundled into a single monthly charge with no separate invoices.

Compared to other telehealth platforms offering similar programs at $179/month or more, Prescriva's transparent all-inclusive pricing keeps access as broad as possible.

---

Frequently Asked Questions

Is compounded semaglutide safe?

Compounded semaglutide is a GLP-1 receptor agonist prepared by a licensed compounding pharmacy. It is not FDA-approved and is not the same as Wegovy or Ozempic. When sourced from a state-licensed 503A compounding pharmacy and prescribed by a qualified provider, it is prepared under strict quality controls. Like all medications, it carries risks and is not appropriate for everyone. Your Prescriva provider reviews your health history before prescribing. This is not medical advice. Consult your healthcare provider.

Is compounded semaglutide FDA-approved?

No. Compounded medications are not FDA-approved. Compounding pharmacies are regulated by the FDA under Section 503A and 503B of federal law, but compounded drugs do not go through the same approval process as commercially manufactured brand-name medications.

How is compounded semaglutide different from Ozempic?

Compounded semaglutide is not the same product as Ozempic. Ozempic is an FDA-approved brand-name drug manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy under a separate regulatory pathway. The two are not interchangeable, and compounded semaglutide is not FDA-approved.

How long until I see results?

Most people begin noticing reduced appetite within the first 1-2 weeks. Visible weight loss typically begins within the first month and becomes more pronounced through months 2-6 as doses increase. In the STEP 1 clinical trial of branded, FDA-approved semaglutide (Wegovy), participants lost an average of 14.9% of body weight over 68 weeks. Compounded semaglutide has not been separately studied in equivalent trials, and these results should not be assumed to apply to compounded formulations. Results may vary. Individual results depend on adherence to treatment and lifestyle changes.

What are the side effects of compounded semaglutide?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are typically most pronounced in the first few weeks and tend to decrease over time. Serious side effects are rare but include a risk of thyroid tumors (based on animal data), pancreatitis, and gallbladder disease. Your provider will review your full risk profile.

Who reviews my case at Prescriva?

Every assessment is reviewed by a licensed healthcare provider, a clinician or nurse practitioner who is licensed in your state. They review your health history, assess your eligibility, and determine the appropriate starting dose. You are not getting an algorithm: you are getting a real clinical review.

---

Disclaimer

*Compounded medications are not FDA-approved. Compounded semaglutide is not the same as Ozempic or Wegovy and should not be considered equivalent to any FDA-approved product. Results may vary. Individual results depend on adherence to treatment and lifestyle changes. This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any new medication or weight loss program. Prescriva's compounded medications are dispensed by state-licensed 503A compounding pharmacies.*

---

Sources:

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." *New England Journal of Medicine.* 2021. PMID: [33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." *The Lancet.* 2021. PMID: [33667417](https://pubmed.ncbi.nlm.nih.gov/33667417/)
3. Ard J, Fitch A, Fruh S, Herman L. "Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists." *Advances in Therapy.* 2021. PMID: [33977495](https://pubmed.ncbi.nlm.nih.gov/33977495/)